Litton Mark James - Insider Non-Derivative Transactions at Athira Pharma, Inc. (ATHA) - (SEC)
Updated on December 12, 2024.
According to recent SEC insider information filed on Sep 5, 2024, Litton Mark James's relationship to Athira Pharma, Inc. (ATHA) is Director,Officer (President and CEO), and currently has 159,365 shares of Common Stock.
The chart below shows the number of shares owned, and the table shows the recent insider transactions.
You can see similar information for other ATHA insiders.
Data Source: SEC.
Litton Mark James - Insider Non-Derivative Transactions of ATHA Common Stock
Litton Mark James - Insider Non-Derivative Transactions at ATHA
Items per page:
0 of 0
| Date | Transaction | No. of Shares | Price Per Share | Shares Owned After Transactions |
|---|---|---|---|---|
| Sep 6, 2024 | Sell -- (Common Stock) | 5032 | 0.57 | 159365 |
| Sep 4, 2024 | Acquisition -- (Common Stock) | 20000 | 0 | 164397 |
| Jan 6, 2024 | Sell -- (Common Stock) | 4820 | 2.91 | 144397 |
| Jan 5, 2024 | Acquisition -- (Common Stock) | 20000 | 0 | 149217 |
| Nov 19, 2022 | Acquisition -- (Common Stock) | 662 | 2.74 | 129217 |